1-3 of 3
Tessa Holyoake, MD
Close
Sort by
Journal Articles

Mtss1 Suppresses BCR-ABL Induced Cell Migration and Is Downregulated in CML Stem Cells.

Mirle Schemionek, Shuchi Agrawal, PhD, Martin Stehling, PhD, Daniel G. Tenen, MD, Ashley Hamilton, Tessa Holyoake, MD, PhD, Ulrich Steidl, MD, PhD, Wolfgang E. Berdel, MD, Albrecht Schwab, MD, Carsten Mùˆller-Tidow, MD, Steffen Koschmieder, MD
Journal: Blood
Blood (2008) 112 (11): 1077.
https://doi.org/10.1182/blood.V112.11.1077.1077
Published: 2008
Journal Articles

Normal Short-Term but Reduced Long-Term Engraftment Capacity of CML Hematopoietic Cells with Skewed Myeloid Lineage Differentiation Is Seen in an Improved Mouse Model of Human Hematopoiesis.

Jeff Tauer, Leonard Shultz, PhD, Tessa Holyoake, MD, Ravi Bhatia, MD
Journal: Blood
Blood (2007) 110 (11): 3383.
https://doi.org/10.1182/blood.V110.11.3383.3383
Published: 2007
Journal Articles

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Stefan Balabanov, MD, PhD, Patrick Ziegler, PhD, Ulricke Hartmann, Winfried Kammer, PhD, Mhairi Copland, MD, Martin Priemer, Thomas Wilhelm, Carsten Bokemeyer, MD, Lothar Kanz, MD, Tessa Holyoake, MD, Alfred Nordheim, PhD, Tim Bruemmendorf, MD
Journal: Blood
Blood (2005) 106 (11): 1997.
https://doi.org/10.1182/blood.V106.11.1997.1997
Published: 2005